ALLIANCE PHARMA PLC

Remuneration Information • Oct 28, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7944N

Alliance Pharma PLC

28 October 2016

	28 October 2016

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Share Options

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that on 27th October 2016 it awarded the following options over ordinary shares of the Company to certain Directors.

Name	Position	Number of Share Options Awarded	Exercise price per Share	Date of vesting	Percentage of issued ordinary share capital
Andrew Franklin	Chief Financial Officer	155,000	47.50	October 2018	0.033
Andrew Franklin	Chief Financial Officer	400,000	47.50	October 2020	0.085
Peter Butterfield	Deputy Chief Executive Officer	200,000	47.50	October 2018	0.042
Peter Butterfield	Deputy Chief Executive Officer	1,000,000	47.50	October 2020	0.212

The vesting of the awards that are scheduled to vest in October 2018 is subject to continued employment and the vesting of the awards that are scheduled to vest in October 2020 is subject to continued employment and the satisfaction of certain performance conditions.

For further information:

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive Andrew Franklin, Chief Financial Officer
Sarah Robinson, Company Secretary
www.alliancepharma.co.uk
Buchanan	+ 44 (0) 20 7466 5000
Mark Court / Sophie Cowles / Jane Glover
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black / Toby Adcock

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international specialty pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

1. Andrew Franklin

2. Peter Butterfield

2

Reason for the notification

a)

Position/status

1. Chief Financial Officer

2. Deputy Chief Executive Officer

b)

Initial notification /Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Alliance Pharma plc

b)

LEI

n/a

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Options to subscribe for new ordinary shares of 1p each

ISIN: GB0031030819

b)

Nature of the transaction

Grant of options

c)

Price(s) and volume(s)

Exercise Price(s)	Volume(s)
## 1. 47.5p per share ## 2. 47.5p per share	## 1. 555,000 ## 2. 1,200,000

d)

Aggregated information

- Aggregated volume

- Price

Total 1,755,000 options granted at a price of 47.5p per share

e)

Date of the transaction

27 October 2016

f)

Place of the transaction

Outside of trading venue

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHAKFDKABDDCKB